Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas.

dc.contributor.author

Mao, Rui

dc.contributor.author

Li, Kan

dc.contributor.author

Cai, Jian-Qiang

dc.contributor.author

Luo, Sheng

dc.contributor.author

Turner, Megan

dc.contributor.author

Blazer, Dan

dc.contributor.author

Zhao, Hong

dc.date.accessioned

2019-10-01T13:32:23Z

dc.date.available

2019-10-01T13:32:23Z

dc.date.issued

2019-08-30

dc.date.updated

2019-10-01T13:32:23Z

dc.description.abstract

OBJECTIVE:The aim of this study was to determine whether adjuvant chemotherapy (AC) provides a survival benefit in patients with nonmetastatic poorly differentiated colorectal neuroendocrine carcinomas (CRNECs) following resection. BACKGROUND:There is little evidence to support the association between use of AC and improved overall survival (OS) in patients with CRNECs. METHODS:Patients with resected non-metastatic CRNECs were identified in the National Cancer Database (2004-2014). Inverse probability of treatment weighting (IPTW) method was used to reduce the selection bias. IPTW-adjusted Kaplan-Meier curves and Cox proportional hazards models were used to compare OS of patients in different treatment groups. RESULTS:A total of 806 patients diagnosed between 2004 and 2014 met the study entry criteria. Of these, 394 patients (48.9%) received AC. IPTW-adjusted Kaplan-Meier curves showed that median OS was significantly longer for AC versus observation [57.4 (interquartile range, IQR, 14.8-153.8) vs 38.2 (IQR, 10.4-125.4) months; P = 0.007]. In IPTW-adjusted Cox proportional hazards regression analysis, AC was associated with a significant OS benefit [hazard ratio (HR) = 0.73, 95% confidence interval (CI) 0.64-0.84; P < 0.001]. The results were consistent across subgroups stratified by pathologic T stage, pathologic N stage, and surgical margin status. Subgroup analysis according to tumor location demonstrated improved OS in the adjuvant therapy cohort among patients with left-sided neuroendocrine carcinomas (HR, 0.55; 95% CI, 0.44-0.68), but not in those with right-sided disease (HR, 0.89; 95% CI, 0.74-1.07). CONCLUSIONS:Patients with nonmetastatic CRNECs may derive survival benefit from AC. These findings support current guidelines recommending AC in patients with poorly differentiated neuroendocrine carcinomas in the colon and rectum. Efforts in education and adherence to national guidelines for NECs are needed.

dc.identifier.issn

0003-4932

dc.identifier.issn

1528-1140

dc.identifier.uri

https://hdl.handle.net/10161/19353

dc.language

eng

dc.publisher

Ovid Technologies (Wolters Kluwer Health)

dc.relation.ispartof

Annals of surgery

dc.relation.isversionof

10.1097/sla.0000000000003562

dc.title

Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas.

dc.type

Journal article

duke.contributor.orcid

Luo, Sheng|0000-0003-4214-5809

pubs.begin-page

1

pubs.end-page

1

pubs.organisational-group

School of Medicine

pubs.organisational-group

Duke

pubs.organisational-group

Duke Clinical Research Institute

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Biostatistics & Bioinformatics

pubs.organisational-group

Basic Science Departments

pubs.publication-status

Published

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2019Mao_et_al2019Ann_Surg.pdf
Size:
399.71 KB
Format:
Adobe Portable Document Format
Description:
Published version